Apex’s team has been involved in the development of 80+ investigational products and more than 40 new drugs to market.
- Diabetes
- A Double Blind, Randomized, Comparator-Controlled Study in Subjects with Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCI versus Glimeperide on the Rate of Progression of Atherosclerotic Disease as Measured by Carotid Intima-Media Thickness
- Insulin Glulisine Administered Premeal Vs. Postmeal in Adult Subjects with Type 2 Diabetes Mellitus Receiving Lantus (insulin glargine) as Basal insulin: A Multicenter, Randomized, Parallel, Open Label Clinical Study
- A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety and Tolerability of Pioglitazone HCl (Actos) in Combination with TAK-536 in Subjects with Type 2 Diabetes
- Hypertension
- The African-American Study of Kidney Disease and Hypertension (AASK) Trial
- NAC-MD-01: A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed-Dose Combination in Patients With Stage 1 or 2 Essential Hypertension
- Hyperlipidemia
- Chronic Kidney Disease
- CTAP101-CL-3001 Protocol Title (Study Name): A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects with Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
- CP505.1003: A Multi-Center, Double-Blind, Two-Arm, Placebo-Controlled, Randomized Safety And Tolerability Study Of Ctp-499 In Non-Dialysis Patients With Stage 3 Chronic Kidney Disease
- Other Studies:
- Cardiovascular Disease
- Osteoarthritis
- Rheumatoid Arthritis
- Pain Management
- Neuropathy
- Gynecology
- Male Health
- Ophthalmology
- Oncology